MGVS’s core technology is based on an integrative approach for the treatment of cardiovascular disease. The innovative combination of two cell types and two genes (MultiGeneAngio) or the combination of cells, genes and a synthetic graft (MultiGeneGraft) that work synergistically, are currently harnessed to provide effective therapies for patients with peripheral arterial disease (PAD), coronary artery disease (CAD) and patients with Renal disease who need hemodialysis.
MGVS’s leading product, MultiGeneAngio, is currently intended for PAD patients. PAD is characterized by narrowing or occlusion of vessels supplying blood to the lower limbs, most often due to atherosclerosis. Symptoms of PAD include claudication that may progress to critical limb ischemia manifested by rest pain, tissue loss and gangrene, which eventually may necessitate amputation. MultiGeneAngio has an additional potential indication, as treatment for Coronary Artery Disease (CAD) patients that suffer from symptoms such as chest pain (angina) and shortness of breath that may progress towards a fatal heart attack. Injection of MultiGeneAngio directly into an ischemic area of the heart may improve blood flow to this area through expansion of collateral blood vessels.
MGVS’s MultiGeneGraft may provide renal disease patients with a long-lasting dialysis access site. The uncoated small caliber synthetic grafts that are currently used for creating access sites suffer from a high failure rate. MultiGeneGraft is coated with endothelial cells, resulting in an improved long-term patency rate. A pre-clinical study with MultiGeneGraft as arteriovenous access in a mini-pig model was recently completed, supporting the safety and efficacy of MultiGeneGraft for this indication.
MGVS’s products are based on the patient's own cells, isolated from a short vein segment stripped from the patient's arm under local anesthesia. The isolated cells are activated by the insertion of specific genes and then re-introduced to the patient. It is anticipated that MGVS’s therapeutic modalities will improve blood flow through expansion of collateral blood vessels or by a modified synthetic graft with improved long term patency.MGVS’s cell transfer approach results in secretion of multiple factors by the activated autologous cells, closely resembling the endogenous process of blood vessel formation and remodeling.